Merck & Co. Stock

$84.12

0.00%

NYSE, Aug 30, 01:34 am CET

ISIN

US58933Y1055

Symbol

MRK

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Merck & Co. Stock price

$84.12

+2.81 3.46% 5Y

NYSE, Closing price Fri, Aug 29 2025

+0.91 1.09%

ISIN

US58933Y1055

Symbol

MRK

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$210.1b

Enterprise Value

$236.9b

Net debt

$26.8b

Cash

$8.6b

Shares outstanding

2.5b

Valuation (TTM | estimate)

P/E

12.9 | 9.3

P/S

3.3 | 3.2

EV/Sales

3.7 | 3.6

EV/FCF

16.1

P/B

4.3

Dividends

DPS

$3.12

Yield 1Y | 5Y

3.7% | 3.0%

Growth 1Y | 5Y

5.4% | 7.7%

Payout 1Y | 3Y

46.3% | 70.5%

Increased

14 Years

Financials (TTM | estimate)

Revenue

$63.6b | $65.4b

EBITDA

$28.5b | $30.3b

EBIT

$23.9b | $27.2b

Net Income

$16.4b | $22.5b

Free Cash Flow

$14.7b

Growth (TTM | estimate)

Revenue

1.8% | 1.9%

EBITDA

3.4% | 5.4%

EBIT

1.9% | 12.2%

Net Income

19.4% | 31.7%

Free Cash Flow

12.0%

Financial Health

Equity Ratio

39.6%

Return on Equity

37.0%

ROCE

26.1%

ROIC

20.7%

Debt/Equity

0.7

EPS

$6.5

FCF per Share

$5.9

Short interest

1.1%

Employees

74k

Rev per Employee

$870.0k

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Merck & Co. Stock Analysis

Unlock Scores for Free

32 Analysts have issued a Merck & Co. forecast:

19x Buy

59%

13x Hold

41%

More details on Analyst Estimates Including Price Targets

32 Analysts have issued a Merck & Co. forecast:

Buy

59%

Hold

41%

Analyst Estimates with Stock Price Targets

Financial data from Merck & Co.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	63,616 63,616	2% 2% 100%
- Direct Costs	13,794 13,794	9% 9% 22%
Gross Profit	49,822 49,822	5% 5% 78%
- Selling and Administrative Expenses	10,733 10,733	3% 3% 17%
- Research and Development Expense	15,221 15,221	13% 13% 24%
EBITDA	28,469 28,469	3% 3% 45%
- Depreciation and Amortization	4,601 4,601	12% 12% 7%
EBIT (Operating Income) EBIT	23,868 23,868	2% 2% 38%
Net Profit	16,406 16,406	19% 19% 26%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Merck & Co. Stock News

Positive

Seeking Alpha

●

one day ago

Top 10 High-Yield Dividend Stocks For September 2025

My watchlist outperformed SPY and VYM since July 1st, offering higher yield and competitive total returns, despite trailing benchmarks year-to-date. The strategy focuses on high-quality, attractively valued, high-yield stocks, aiming for a long-term CAGR of 12% and strong dividend growth. Since inception, the watchlist achieved a 15.61% CAGR and an 83.5% success rate in positive returns, valida...

Neutral

Business Wire

●

3 days ago

Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides New Results for Vericiguat in Patients with Chronic Heart Failure and Reduced Ejection Fraction. Results presented at ESC 2025.

Neutral

FXEmpire

●

5 days ago

Merck: Buy the Next Dip Despite Short-Term Pressures

Merck's Q2 2025 results highlight strong growth in Keytruda and Animal Health, while its bullish chart pattern and low valuation make it a compelling long-term buy.

More Merck & Co. News

Company Profile

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Head office	United States
CEO	Robert Davis
Employees	74,000
Founded	1891
Website	www.merck.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now